YZYali Zhong

Yali Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yali Zhong has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Jahn Martin Nesland

    Department of Pathology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway

    4 shared publications
  • Zhenhe Suo

    Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China

    4 shared publications
  • Jian Guo Wen

    Pediatric Urodynamic Center, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan Joint International Pediatric Urodynamic Laboratory, Zhengzhou, China

    3 shared publications
  • Xiaoran Li

    Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

    3 shared publications
  • Fuyou Zhou

    Anyang Tumor Hospital, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Henan key medical laboratory of precise prevention and treatment of esophageal cancer, Anyang 455001, Henan Province, China

    2 shared publications
  • Junsheng Wang

    2 shared publications

Latest Publications

  • Open Access

    MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer

    by Xiaoli Li, Yasai Ji, Gaoyang Han, Xiaoran Li, Zhirui Fan, Yaqing Li, Yali Zhong, Jing Cao, Jing Zhao, Mingzhi Zhang, et al.

    Cancer cells exhibit an altered metabolism, which is characterized by a preference for aerobic glycolysis more than mitochondrial oxidation of pyruvate. Mitochondrial pyruvate carrier 1 (MPC1) and mitochondrial pyruvate carrier 2 (MPC2) play a bottleneck role by transporting pyruvate into mitochondrial through the mitochondrial inner membrane. Therefore, their protein expression in cancers may be of clinical consequences. There are studies showing low levels of MPC1 expression in colon, kidney and lung cancers, and the expression of MPC1 correlates with poor prognosis. However, the expression status of MPC1 and MPC2 in prostate cancer (PCA) is unclear. In this study, expression of MPC1 and MPC2 in LNCaP and DU145 prostate cancer cell lines was examined by immunocytochemistry (ICC) and Western blotting. Compared to the LNCaP cells, lower levels of MPC1 and MPC2 expression in the DU145 cell line was identified. We then extended our study to 88 patients with prostate cancer who underwent transurethral electro-vaporization of prostate or radical prostatectomy at the First Affiliated Hospital of Zhengzhou University, Henan, China. Patient-derived paraffin embedded PCA specimens were collected for immunohistochemistry (IHC). Correlations with clinicopathologic factors were evaluated by Chi-square or Fisher´s exact probability tests. Overall survival (OS) rates were determined using the Kaplan-Meier estimator. The Cox proportional hazard regression model was used in univariate analysis and multivariate analysis to identify factors significantly correlated with prognosis. Linear regression analysis revealed that MPC1 expression level was positively correlated with MPC2 expression (r = 0.375, P = 0.006) in the prostate cancers. MPC1 expression was negatively associated with UICC stage (P = 0.031). While UICC stage (P < 0.001) and lymph node metastasis (P = 0.002) were negatively associated with MPC2 expression. Positive MPC1 or MPC2 expression in cancer tissues was significantly associated with higher OS (P < 0.05). The multivariate analysis showed that both MPC1 and MPC2 expressions in PCA were independent prognostic factors for higher OS (For MPC1: RR = 0.654, 95% CI: 0.621-0690, P < 0.001; For MPC2: RR = 0.696, 95% CI: 0.660-0.734, P < 0.001). Our study indicates that MPC1 and MPC2 expressions are of prognostic values in PCAs and that positive expression of MPC1 or MPC2 is a predictor of favorable outcome.


    • 1 January 2016
      • Vol. 36  (1) , 343-9

    Aldehyde Dehydrogenase-1 Expression Predicts Unfavorable Outcomes in Patients with Esophageal Squamous Cell Carcinoma.

    by Yasai Ji, Xiaoli Li, Yaqing Li, Yali Zhong, Jing Cao, Ruiping Xu, Junsheng Wang, Fuyou Zhou, Xiaoran Li, Dandan Yu, et al.

    Aldehyde dehydrogenase-1 (ALDH1) has been shown to be a potential cancer stem cell marker in different types of cancer. However, the role of its expression in tumor cells and the microenvironment in different types of cancer is still controversial. ALDH1 protein was immunohistochemically investigated and analyzed in 157 samples of surgically dissected esophageal squamous cell carcinoma (ESCC) tissues. ALDH1 protein expression in ESCC tumor cells was significantly associated with poor differentiation (p0.05). High expression of cancer stem cell marker ALDH1 in ESCC cells may thus portend a poor prognosis. However, its expression in the tumor microenvironment did not appear to have a role in ESCC behavior. More studies are warranted to find out the mechanisms to explain this.


    • 1 October 2015
      • Vol. 35  (10) , 5533-8

    Decreased Expression of PDHE1α Predicts Worse Clinical Outcome in Esophageal Squamous Cell Carcinoma.

    by Yali Zhong, Ruixia Huang, Xiaoran Li, Ruiping Xu, Fuyou Zhou, Junsheng Wang, Huijie Fan, Mariusz Goscinski, Mingzhi Zhang, Jian-Guo Wen, et al.

    Aerobic glycolysis is an important hallmark of cancer cells. Deficiency of pyruvate dehydrogenase component α subunit (PDHE1α) leads to mitochondrial dysfunction and promotes glycolysis. Therefore, studies on the expression of PDHE1α in cancer are warranted. The PDHE1α protein was immunohistochemically investigated and analyzed in 157 samples of surgically dissected esophageal squamous cell carcinoma (ESCC) and 21 'normal' esophageal epithelia tissues. PDHE1α protein expression was lower in ESCC. Absence of PDHE1α protein expression in tumor cells was found in 77.1% of cases. Negativity for PDHE1α protein in tumor cells was correlated with poor tumor differentiation (p<0.05) and shorter overall survival (p<0.05). Lack of PDHE1α protein expression in ESCC is associated with poor prognosis. Our findings also verify the existence of aerobic glycolysis switch in ESCC, and strongly advocate novel therapeutic strategies in reversing the Warburg effect in tumors.


    • 1 July 2015
      • Vol. 35  (7) , 3743-53

    Mitochondrial DNA Deficiency in Ovarian Cancer Cells and Cancer Stem Cell-like Properties.

    by Ruixia Huang, Junbai Wang, Yali Zhong, Yishan Liu, Trond Stokke, Claes G Trope, Jahn M Nesland, Zhenhe Suo

    A low quantity of mitochondrial DNA (mtDNA) is a risk factor in a variety of tumor types. However, it is unclear how mtDNA reduction influences tumor behavior. mtDNA-deficient ovarian cancer cells were established by ethidium bromide (EtBr) treatment with additive combination of pyruvate and uridine. The mtDNA-deficient cells had a low growth and colony-forming efficiency compared to the control cells. RNA sequencing revealed down-regulation of mitochondrion-related genes and up-regulation of genes related to cell proliferation and anti-apoptosis. The expression of genes involved in cancer metastasis, proliferation, angiogenesis, drug resistance and cancer cell stemness were also up-regulated. Intriguingly, cancer stem cell markers CD90 and CD117 were both up-regulated by EtBr dose-dependently in both cell lines. MtDNA deficiency may induce ovarian cancer stem cell-like properties through different ways in vitro, therefore contributing to different tumor behaviors.